3G0 Stock Overview A clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Altimmune, Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Altimmune Historical stock prices Current Share Price US$7.75 52 Week High US$13.70 52 Week Low US$5.02 Beta 0.15 1 Month Change -2.09% 3 Month Change 24.92% 1 Year Change -8.88% 3 Year Change 0.66% 5 Year Change 391.28% Change since IPO -96.32%
Recent News & Updates
Altimmune, Inc. Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease at The Liver Meeting 2024 Nov 16
Third quarter 2024 earnings released: US$0.32 loss per share (vs US$0.39 loss in 3Q 2023) Nov 13
New major risk - Revenue and earnings growth Nov 13
Altimmune, Inc. Appoints Greg Weaver as Chief Financial Officer Nov 12
Altimmune, Inc. Announces Successful Completion of End-of-Phase 2 Meeting with FDS for Pemvidutide in the Treatment of Obesity Nov 08
Altimmune, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 04 See more updates
Altimmune, Inc. Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease at The Liver Meeting 2024 Nov 16
Third quarter 2024 earnings released: US$0.32 loss per share (vs US$0.39 loss in 3Q 2023) Nov 13
New major risk - Revenue and earnings growth Nov 13
Altimmune, Inc. Appoints Greg Weaver as Chief Financial Officer Nov 12
Altimmune, Inc. Announces Successful Completion of End-of-Phase 2 Meeting with FDS for Pemvidutide in the Treatment of Obesity Nov 08
Altimmune, Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 04
High number of new directors Oct 16
High number of new directors Oct 04
Altimmune, Inc. Completes Enrollment in Phase 2B Impact Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (Mash) Oct 01
Altimmune, Inc., Annual General Meeting, Sep 26, 2024 Aug 16
First half 2024 earnings released: US$0.69 loss per share (vs US$0.72 loss in 1H 2023) Aug 09
Altimmune, Inc. to Report Q2, 2024 Results on Aug 08, 2024 Aug 01
Altimmune, Inc. Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology Jul 25
Altimmune, Inc. Announces Demise of Richard Eisenstadt, Chief Financial Officer Jun 26
Altimmune, Inc. Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity at the American Diabetes Association’s 84th Scientific Sessions Jun 24
Altimmune, Inc. Presents Data at EASL International Liver Congress™? 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Jun 06
New major risk - Revenue and earnings growth May 12
First quarter 2024 earnings released: US$0.34 loss per share (vs US$0.40 loss in 1Q 2023) May 09 Pomerantz LLP Announces Filing of Class Action Against Altimmune, Inc. and Certain Officers May 08
Altimmune, Inc. to Report Q1, 2024 Results on May 09, 2024 May 03
Full year 2023 earnings released: US$1.66 loss per share (vs US$1.81 loss in FY 2022) Mar 28
New major risk - Revenue and earnings growth Mar 27
Altimmune, Inc. Announces Impairment Loss for the Three Months Ended December 31, 2023 Mar 27
Altimmune, Inc. to Report Q4, 2023 Results on Mar 27, 2024 Mar 21
Altimmune, Inc. Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide Dec 01
Third quarter 2023 earnings released: US$0.39 loss per share (vs US$0.48 loss in 3Q 2022) Nov 08
Altimmune, Inc. to Report Q3, 2023 Results on Nov 07, 2023 Nov 02
Altimmune, Inc. Grants Fast Track Designation by FDA for Pemvidutide for the Treatment of Non Alcoholic Steatohepatitis (Nash) Oct 27
Altimmune, Inc., Annual General Meeting, Sep 28, 2023 Aug 18
Altimmune, Inc. to Report Q2, 2023 Results on Aug 10, 2023 Aug 04
Altimmune, Inc. Announces Initiation of Phase 2b Impact Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Al Alcoholic Steatohepatitis Aug 02
Altimmune, Inc. to Report Q1, 2023 Results on May 11, 2023 May 05
Altimmune, Inc. Appoints Raymond Jordt as Chief Business Officer Jan 05 Altimmune, Inc. Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease
Third quarter 2022 earnings released: US$0.48 loss per share (vs US$0.81 loss in 3Q 2021) Nov 16
Third quarter 2022 earnings released: US$0.48 loss per share (vs US$0.81 loss in 3Q 2021) Nov 11
Altimmune, Inc. to Report Q3, 2022 Results on Nov 10, 2022 Nov 04
Altimmune, Inc. Announces First Dosing of All Subjects in Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight Sep 29
Altimmune, Inc. Announces Significant Reductions in Liver Fat Content and Body Weight in 12-Week Phase 1b Clinical Trial of Pemvidutide in Subjects with NAFLD Sep 15
Altimmune, Inc., Annual General Meeting, Sep 29, 2022 Aug 17
Second quarter 2022 earnings released: US$0.42 loss per share (vs US$0.60 loss in 2Q 2021) Aug 13
Altimmune, Inc. to Report Q2, 2022 Results on Aug 11, 2022 Aug 05
First quarter 2022 earnings released: US$0.44 loss per share (vs US$0.38 loss in 1Q 2021) May 13
Altimmune, Inc. to Report Q1, 2022 Results on May 12, 2022 May 06
Insufficient new directors Apr 27
Altimmune Announces Initiation of 48-Week Phase 2 Momentum Trial of Pemvidutide in Obesity Apr 03
Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat Mar 16
Altimmune Announces FDA Clearance of Pemvidutide (ALT-801) IND for Obesity Feb 01
Insufficient new directors Jan 01
Insufficient new directors Dec 02
Third quarter 2021 earnings released: US$0.81 loss per share (vs US$0.54 loss in 3Q 2020) Nov 10
Altimmune Announces Positive Results from 12-Week Phase 1 Clinical Trial of ALT-801 (Pemvidutide) in Overweight and Obese Volunteers Oct 01
Altimmune, Inc. Reports an Impairment on Construction-In-Progress for the Three Months Ended June 30, 2021 Aug 12
Second quarter 2021 earnings released: US$0.60 loss per share (vs US$0.94 loss in 2Q 2020) Aug 11
Altimmune Announces Update on AdCOVID™ Phase 1 Clinical Trial Jun 30
Altimmune Announces Positive Interim Data from ALT-801 Phase 1 Trial in Overweight and Obese Volunteers Jun 17
Forecast breakeven pushed back to 2024 May 30
Altimmune, Inc. Demonstrates Strong Neutralization of South African Variant in Preclinical Study of Intranasal AdCOVID™ May 27
First quarter 2021 earnings released: US$0.38 loss per share (vs US$0.26 loss in 1Q 2020) May 18
Forecast breakeven pushed back to 2025 May 18
Altimmune Announces New Preclinical Data for AdCOVID™ Demonstrating Sterilizing Immunity After a Single Intranasal Dose May 11
Altimmune, Inc. Announces Additional Preclinical Data for Its Single Dose Intranasal COVID-19 Vaccine Candidate, AdCOVID Mar 16
Full year 2020 earnings released: US$1.91 loss per share (vs US$1.60 loss in FY 2019) Feb 27
Revenue beats expectations Feb 27
Altimmune, Inc. Commences Enrollment in Phase 1 Clinical Trial of AdCOVID- A Needle-Free, Single-Dose Intranasal Covid-19 Vaccine Candidate Feb 27
Altimmune, Inc. to Report Fiscal Year 2020 Results on Feb 25, 2021 Feb 23
Altimmune, Inc. Announces FDA Clearance of AdCOVID™ IND Application Feb 18
New 90-day high: €17.57 Feb 11
New 90-day high: €12.28 Jan 26
Altimmune, Inc. Begins Multinational Phase 2 Clinical Trial of HepTcellTM, a Novel Immunotherapeutic for the Treatment of Chronic Hepatitis B Dec 31
Altimmune Provides an Update on its Investigational New Drug Application for a Phase 1 AdCOVID™ Clinical Trial Dec 24
Altimmune Announces Submission of Investigational New Drug Application To the U.S. Food and Drug Administration to Commence A Phase 1 Clinical Study of Its Single-Dose Intranasal COVID-19 Vaccine Candidate, AdCOVID Nov 27
Third quarter 2020 earnings released: US$0.54 loss per share Nov 11
Revenue beats expectations Nov 11
Altimmune, Inc. Adds Lonza as a Manufacturing Partner for Supply of AdCOVID its Single-Dose Intranasal Vaccine Candidate for COVID-19 Nov 11
New 90-day low: €7.08 Nov 09
Altimmune, Inc. to Report Q3, 2020 Results on Nov 10, 2020 Nov 05
New 90-day low: €9.42 Oct 21
Altimmune and UAB Announces Publication of Compelling Pre-clinical Data for AdCOVID™ Intranasal COVID-19 Vaccine Candidate Oct 13
First half earnings released Aug 12
Altimmune, Inc. to Report Q2, 2020 Results on Aug 12, 2020 Aug 06
Altimmune, Inc. has completed a Follow-on Equity Offering in the amount of $114.99837 million. Jul 18
Altimmune, Inc.(NasdaqGM:ALT) dropped from Russell Microcap Value Index Jul 03 Shareholder Returns 3G0 DE Biotechs DE Market 7D -14.0% -3.5% -2.0% 1Y -8.9% -14.7% 6.9%
See full shareholder returns
Return vs Market: 3G0 underperformed the German Market which returned 6.9% over the past year.
Price Volatility Is 3G0's price volatile compared to industry and market? 3G0 volatility 3G0 Average Weekly Movement 15.7% Biotechs Industry Average Movement 6.8% Market Average Movement 4.9% 10% most volatile stocks in DE Market 11.3% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: 3G0's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 3G0's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company’s lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus.
Show more Altimmune, Inc. Fundamentals Summary How do Altimmune's earnings and revenue compare to its market cap? 3G0 fundamental statistics Market cap €562.37m Earnings (TTM ) -€99.21m Revenue (TTM ) €49.84k
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) 3G0 income statement (TTM ) Revenue US$52.00k Cost of Revenue US$79.35m Gross Profit -US$79.30m Other Expenses US$24.22m Earnings -US$103.52m
Last Reported Earnings
Sep 30, 2024
Earnings per share (EPS) -1.46 Gross Margin -152,503.85% Net Profit Margin -199,076.92% Debt/Equity Ratio 0%
How did 3G0 perform over the long term?
See historical performance and comparison
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2024/12/23 09:32 End of Day Share Price 2024/12/20 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Altimmune, Inc. is covered by 12 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Mayank Mamtani B. Riley Securities, Inc. Joshua Schimmer Evercore ISI Liisa Bayko Evercore ISI
Show 9 more analysts 
